Becton, Dickinson and Company Reports Earnings Results for the Fourth Quarter Ended September 30, 2021
November 04, 2021 at 06:00 am EDT
Share
Becton, Dickinson and Company reported earnings results for the fourth quarter ended September 30, 2021. For the fourth quarter, the company reported sales was USD 5,135 million compared to USD 4,784 million a year ago. Net income was USD 265 million compared to USD 128 million a year ago. Basic earnings per share from continuing operations was USD 0.85 compared to USD 0.36 a year ago. Diluted earnings per share from continuing operations was USD 0.84 compared to USD 0.36 a year ago.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
